Clinical Trial Update: F901318 Multiple Ascending Dose Study [Phase 1]

View source ↗

Summary

A Phase 1 multiple ascending dose study of F901318 for invasive aspergillosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Drugs mentioned

• F901318

Snippet

Sponsor: F2G Biotech GmbH | Conditions: Invasive Aspergillosis | Phase 1 | Status: COMPLETED